Pomerantz Law Firm Investigates enGene Therapeutics for Potential Securities Fraud

The Pomerantz Law Firm is investigating potential securities fraud involving enGene Therapeutics Inc. (NASDAQ: ENGN) following the release of disappointing clinical trial results that caused its stock price to drop by 80.56%. The firm seeks investors who may join a class-action lawsuit.

By Pomerantz LLP · PR Newswire · June 4, 2026, 14:00 UTC

Tickers: $ENGN

Topics: clinical trial results securities fraud stock price drop

Read the full article at PR Newswire

More World news

Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC
PVH Corp. Announces Global Workforce Reduction of Approximately 4% Seeking Alpha · November 12, 2026, 13:34 UTC
Analysis Reveals 75% of Americans Reside in Car-Dependent Areas PR Newswire · November 12, 2026, 13:38 UTC
ASML Positioned for Potential Stock Split Amid Surging AI Demand and Record Results Motley Fool · November 12, 2026, 13:31 UTC